Crucell gets legal over PER.C6 infringement
against CEVEC Pharmaceuticals, which claims the company has
violated Crucell's PER.C6 technology's European patent.
Crucell claims that CEVEC, formed in Germany in 2001, is attempting to establish a business on the basis of a human cell line that has features similar to Crucell's patented PER.C6 technology.
Crucell's fully human PER.C6 cell line is an established technology for the production of antibodies. Crucell licenses its PER.C6 technology to the biopharmaceutical industry on a mostly non-exclusive basis. Licensees and CMO partners include DSM Biologics, GSK, Centocor/J&J and Merck & Co.
Crucell's PER.C6 is a production technology derived from a single healthy, human retinal cell and has become established as one of the best platforms to make vaccines, and has become an established industry standard.
Latterly, the company has started developing its own vaccine products, aided by its positions in PER.C6 and adenoviral vectors.
